カテゴリ： GlobalData, 企業調査, 台湾

Crown Bioscience Inc (6554)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Crown Bioscience Inc (6554) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8020
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：台湾
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Crown Bioscience Inc (Crown Bioscience) is a drug discovery company that provides drug discovery and development services. The company offers antibodies, proteins, cell lines, tumor samples, in vivo and in vitro research reagents. It offers services such as preclinical research services, oncology services, and metabolic disease services, among others. Crown Bioscience provides its preclinical research services in areas of oncology and metabolic disease. The company’s oncology services comprise human surrogate trials, oncology databases, ex vivo services, in vitro services, in vivo services, translational research, preclinical formulations, and drug discovery services. Its metabolic disease services include CVMD databases, and ex vivo services. The company has its operations in the US, China, the UK, and Taiwan. Crown Bioscience is headquartered in Taipei, Taiwan.

Crown Bioscience Inc (6554) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Crown Bioscience Acquires PDX Business Unit from Molecular Response 13
Venture Financing 14
CBT Pharma Raises USD5 Million in Seed Financing 14
Crown Bioscience Raises Funds in Venture Financing 15
Crown Bioscience Raises USD27 Million in Series D Financing 16
Partnerships 17
Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 17
Crown Bioscience Enters into Partnership with Glycotope 18
Crown Bioscience Enters into Partnership with Phanes Therapeutics 19
Crown Bioscience Enters into Co-Development Agreement with Data Sciences International 20
Crown Bioscience and Jackson Lab Enter into Agreement 21
Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 22
Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 23
Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 24
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 25
Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 26
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 27
Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 28
Licensing Agreements 29
Crown Bioscience Enters into Licensing Agreement with University of Utah 29
Crown Bioscience Enters into Licensing Agreement with Shanghai Model Organisms 30
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 31
Crown Bioscience Enters into Licensing Agreement with University of York 32
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 33
Equity Offering 34
Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 34
Crown Bioscience Raises Funds through IPO 35
Acquisition 36
JSR Acquires Crown Bioscience for USD399.7 Million 36
Crown Bioscience Acquires PreClinOmics 38
Crown Bioscience Acquires Preclinical Oncology Services 39
Crown Bioscience Inc – Key Competitors 40
Crown Bioscience Inc – Key Employees 41
Crown Bioscience Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Strategy And Business Planning 43
Jul 13, 2017: Crown Bioscience Expands its Life Science Portfolio 43
Jan 26, 2017: CrownBio Announces Expansion of Life Science Division 44
Jan 24, 2017: Crown Bioscience Announces Expansion of Therapeutic Expertise into Inflammation 45
Jan 12, 2017: Crown Bioscience Expands US Capacity for Cardiovascular & Metabolic Disease Research; Partners with New Iberia Research Center of Louisiana 46
Financial Announcements 47
Aug 10, 2017: Crown Bioscience Announces Second Quarter Results 47
May 19, 2017: Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results 48
Corporate Communications 49
Nov 09, 2017: Crown Bioscience Announcing the 2017 Board of Directors Election Results Dr. Guoliang Yu re-elected as the Chairman 49
Sep 27, 2017: Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role 50
Aug 10, 2017: Crown Bioscience Appoints Dr. Yangzhou Wang as Sr. VP of Global Operations 51
Government and Public Interest 52
Jul 19, 2018: Crownbio supports excellence in translational research with grant award that funds innovative PDX model development in immuno-oncology 52
Nov 17, 2017: CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research 53
Product News 54
Nov 23, 2017: Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring 54
Oct 10, 2017: CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes 55
Sep 13, 2017: CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer 56
Aug 01, 2017: CrownBio Launches Innovative Inflammatory Disease Models to Advance Pre-Clinical Research 57
Other Significant Developments 58
Sep 26, 2018: CrownBio completes validation of prostate cancer patient-derived xenograft (PDX) models 58
Jul 27, 2018: CrownBio Expands Novel Humanized Models for Targeted Immunotherapy Development to San Diego, CA Research Center 59
Feb 20, 2018: Crown Bioscience: CAR T-Cell Therapy Platform 60
Feb 09, 2018: Enhanced MuScreen Platform Revolutionizes Preclinical Development of Immunotherapeutics 61
Jan 09, 2018: Crown Bioscience Launches CrownSyn, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies 62
Apr 19, 2017: Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products 63
Mar 09, 2017: Crown Bioscience Enables Secure Data Real Time Access with the Release of Client Facing Portal 64
Feb 16, 2017: Crown Bioscience Enhances Digital Connectivity with the Release of OncoExpress Technology Platform 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Crown Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Crown Bioscience Acquires PDX Business Unit from Molecular Response 13
CBT Pharma Raises USD5 Million in Seed Financing 14
Crown Bioscience Raises Funds in Venture Financing 15
Crown Bioscience Raises USD27 Million in Series D Financing 16
Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 17
Crown Bioscience Enters into Partnership with Glycotope 18
Crown Bioscience Enters into Partnership with Phanes Therapeutics 19
Crown Bioscience Enters into Co-Development Agreement with Data Sciences International 20
Crown Bioscience and Jackson Lab Enter into Agreement 21
Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 22
Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 23
Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 24
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 25
Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 26
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 27
Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 28
Crown Bioscience Enters into Licensing Agreement with University of Utah 29
Crown Bioscience Enters into Licensing Agreement with Shanghai Model Organisms 30
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 31
Crown Bioscience Enters into Licensing Agreement with University of York 32
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 33
Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 34
Crown Bioscience Raises Funds through IPO 35
JSR Acquires Crown Bioscience for USD399.7 Million 36
Crown Bioscience Acquires PreClinOmics 38
Crown Bioscience Acquires Preclinical Oncology Services 39
Crown Bioscience Inc, Key Competitors 40
Crown Bioscience Inc, Key Employees 41
Crown Bioscience Inc, Other Locations 42
Crown Bioscience Inc, Subsidiaries 42

List of Figures
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Crown Bioscience Inc (6554)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Taisho Pharmaceutical Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Taisho Pharmaceutical Co Ltd (Taisho), a subsidiary of Taisho Pharmaceutical Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets a range of prescription pharmaceutical and self-medication drugs. The company offers products such as lipovitan D, riup, clarith, z …
  • Vanda Pharmaceuticals Inc (VNDA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour …
  • Westdeutsche Immobilien Servicing AG：企業の戦略・SWOT・財務分析
    Westdeutsche Immobilien Servicing AG - Strategy, SWOT and Corporate Finance Report Summary Westdeutsche Immobilien Servicing AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Steward Health Care System LLC：企業の戦略的SWOT分析
    Steward Health Care System LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Warimpex Finanz- und Beteiligungs AG：企業の戦略・SWOT・財務情報
    Warimpex Finanz- und Beteiligungs AG - Strategy, SWOT and Corporate Finance Report Summary Warimpex Finanz- und Beteiligungs AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Antabio SAS：製薬・医療：M&Aディール及び事業提携情報
    Summary Antabio SAS (Antabio) is a biopharmaceutical company that develops novel antibacterials targeting drug-resistant pathogens. The company’s pipeline products comprise Metallo Beta-Lactamases inhibitors, Pseudomonas Biofilms inhibitors and others. It uses in vitro technologies and bacterial dis …
  • China Haisheng Juice Holdings Co Ltd：戦略・SWOT・企業財務分析
    China Haisheng Juice Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Haisheng Juice Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Versartis Inc (VSAR)：製薬・医療：M&Aディール及び事業提携情報
    Summary Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduc …
  • Microsoft Corp (MSFT)：医療機器：M&Aディール及び事業提携情報
    Summary Microsoft Corporation (Microsoft) is a technology-based company that develops, licenses, and supports software products, services, and devices. The company offers a comprehensive range of operating systems, cross-device productivity applications, server applications, business solution applic …
  • Euro-Diagnostica AB：医療機器：M&Aディール及び事業提携情報
    Summary Euro-Diagnostica AB (Euro Diagnostica) is a medical device company that manufactures and markets purified antigens and antibodies. The company offers blood based solutions, developed to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune diseases. It offers product …
  • Groupe PSA：企業の戦略・SWOT・財務分析
    Groupe PSA - Strategy, SWOT and Corporate Finance Report Summary Groupe PSA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Monadelphous Group Ltd (MND)：企業の財務・戦略的SWOT分析
    Monadelphous Group Ltd (MND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • EBSCO Industries Inc.：企業の戦略・SWOT・財務分析
    EBSCO Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary EBSCO Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Latvenergo AS：企業の戦略的SWOT分析
    Latvenergo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • IRX Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary IRX Therapeutics Inc (IRX Therapeutics) is a clinical-stage bioresearch company that develops immunotherapies which reduces the immune suppression. The company provides product that overcomes cancer induced immune suppression and restores anti-tumor response. It offers product IRX-2 which is …
  • The Royal Bank Of Scotland Group Plc
    The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • DiaMedica Therapeutics Inc (DMA)：企業の財務・戦略的SWOT分析
    Summary DiaMedica Therapeutics Inc (DiaMedica), formerly DiaMedica Inc is a clinical-stage biopharmaceutical company which develops innovative medicines for the treatment neurological and kidney diseases. Its lead product candidate DM-199, is a human recombinant protein that treats diabetes type 1 a …
  • McPherson’s Ltd (MCP)：企業の財務・戦略的SWOT分析
    McPherson's Ltd (MCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Evercore Inc：企業のM&A・事業提携・投資動向
    Evercore Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Evercore Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Bayshore Petroleum Corp (BSH)：石油・ガス：M&Aディール及び事業提携情報
    Summary Bayshore Petroleum Corp (Bayshore Petroleum) is an oil and gas company that explores, produces, and develops natural gas and petroleum. The company develops conventional and unconventional oil and gas prospects in North America and across the world. Its CCC technology provides heavy oil and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆